CTOR

Citius Oncology, Inc. (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company founded as a subsidiary of Citius Pharmaceuticals, Inc. and headquartered in New York, New York. The company specializes in developing novel targeted therapies for cancer treatment, with a particular focus on rare blood cancers. Citius Oncology operates as a pre-revenue biotech company, currently advancing its lead drug candidate LYMPHIR through clinical trials for the treatment of cutaneous T-cell lymphoma, a rare form of blood cancer that affects the skin.